Literature DB >> 6183403

Chronic relapsing experimental autoimmune encephalomyelitis. treatment with combinations of myelin components promotes clinical and structural recovery.

U Traugott, S H Stone, C S Raine.   

Abstract

Preliminary results are presented on the treatment of Strain 13 guinea pigs with chronic relapsing experimental autoimmune (allergic) encephalomyelitis (EAE) induced by a single sensitisation with whole spinal cord. Animals were treated at different stages of the disease with injection containing either myelin basic protein (MBP) alone in incomplete Freund's adjuvant (IFA), or MBP in combination with a lipid hapten of myelin, galactocerebroside (GC) in IFA. The rationale for this treatment stemmed from previous work which suggested that MBP was responsible for T cell sensitisation in EAE and that GC was important in producing demyelinating antibodies and that both myelin components were needed in the induction of disease. Although treatment with MBP alone caused some initial stabilisation of the disease process, subsequent relapses occurred in all animals. However, in animals given MBP and GC together, either early or late in the course of the disease, marked clinical improvement has been noted with little or no development of relapses over an observation period of more than one year post-treatment. In addition, evidence of extensive remyelination and oligodendroglial proliferation in CNS lesions has been found in MBP-GC-treated animals suggesting that this therapy might be beneficial for CNS repair and relevant to multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183403     DOI: 10.1016/0022-510x(82)90061-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

Review 1.  Characterization and distribution of lymphocyte subpopulations in multiple sclerosis plaques versus autoimmune demyelinating lesions.

Authors:  U Traugott
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

3.  A new model for multiple sclerosis: chronic experimental allergic encephalomyelitis induced by immunization with cerebral endothelial cell membrane.

Authors:  N Tsukada; C S Koh; N Yanagisawa; A Okano; W M Behan; P O Behan
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

4.  Relapsing subacute demyelinating encephalomyelitis in rats during the course of coronavirus JHM infection.

Authors:  H Wege; R Watanabe; V ter Meulen
Journal:  J Neuroimmunol       Date:  1984-08       Impact factor: 3.478

5.  Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis.

Authors:  F D Lublin
Journal:  Springer Semin Immunopathol       Date:  1985
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.